Research programme: anticancer antibodies - ARIUS/Takeda
Latest Information Update: 16 Jul 2016
At a glance
- Originator ARIUS Research; Takeda
- Class Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in Japan (Parenteral)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 24 Sep 2008 ARIUS Research has been acquired by Roche